Back

Impact of routine cardiovascular medications on contrast induced nephropathy post percutaneous coronary intervention: a national experience

28 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Personalising antithrombotic therapy in percutaneous coronary intervention for acute coronary syndromes: balancing ischaemic protection and bleeding risk Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Osamah Alameen

HMC Heart Hospital, Doha (Qatar)

5 More presentations in this session

Presentation thumbnail
Impact of intravascular imaging guidance on the effects of aspirin-free strategy for percutaneous coronary intervention for acute coronary syndrome: a post-hoc analysis from the STOPDAPT-3 trial
Doctor K. Takabayashi (Shiga, JP)
Abstract Slides
Presentation thumbnail
Temporal trends in the use of P2Y12 inhibitors over 15 years and their impact on in-hospital bleeding and mortality among patients with acute myocardial infarction in Switzerland
Mr J. Loosli (Zurich, CH)
Abstract Slides
Presentation thumbnail
Timing of P2Y12 inhibitor administration in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis
Doctor T. Theodoropoulou (Athens, GR)
Abstract Slides
Presentation thumbnail
Standard versus extended dual antiplatelet therapy after pci in acute coronary syndrome: a systematic review and meta-analysis
Mr A. Gasca (Cali, CO)
Abstract Slides
Presentation thumbnail
Early aspirin withdrawal to P2Y12 monotherapy after PCI for ACS: a systematic review and meta-analysis of randomized controlled trials
Professor M. Saffi (Porto Alegre, BR)
Abstract Slides

Access the full session

Session thumbnail
Personalising antithrombotic therapy in percutaneous coronary intervention for acute coronary syndromes: balancing ischaemic protection and bleeding risk

The Event

Event poster

ESC Congress 2026

28 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Predictors of contrast induced nephropathy in patients with normal renal function undergoing percutaneous coronary intervention - ADAPH score
20 March 2026
thumbnail
Congress Presentation
Intravenous administration of IV-STATIN CARDIOSHIELD during myocardial infarction renders higher cardioprotection than oral atorvastatin given shortly after reperfusion: a translational CMR study
1 September 2019
thumbnail
Congress Presentation
Effect of renin angiotensin system inhibitors on long-term major cardiovascular outcomes in patients with high atherosclerotic cardiovascular risk
23 May 2023
thumbnail
Congress Presentation
Impact of P2Y12 inhibitor pretreatment before coronary angiography in high risk NSTE-ACS: A comparative cohort analysis
21 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources